Cerevanta / Neuro-oncology research services
A clearer compound decision. Before the lab.
For small neuro-oncology biotechs: focused research briefs that bring BBB and ADME predictions together with the literature, so you can decide what deserves the next experiment.
Decision support for research. Not a substitute for experimental validation.
From prediction to next test
A two-page brief. Clear uncertainty. A documented run card.
Our commitments
Evidence over enthusiasm.
01 / Traceable methods
02 / Explicit limitations
03 / A practical next test
The compound brief
Less output.
More understanding.
Built around one compound and one research question, with glioblastoma relevance in view. The deliverable is concise; the reasoning stays visible.
A validation-first approach
Docking conclusions depend on a reproducible redocking check. Where docking is used, the brief should document the reference case, RMSD, and limitations—not imply experimental proof.
Define the decision
A focused question: is this compound worth further investigation, and what evidence would change that decision?
Read predictions in context
BBB and ADME predictions alongside relevant literature, with uncertainty and conflicting evidence made explicit.
Choose the next experiment
What the analysis cannot establish, a recommended next test, and an attached run card to make the computational work traceable.
Work with Cerevanta
Start with one question.
An early-stage service for focused compound assessment. Available offerings and fees are listed below; no invented tiers or open-ended research promises.
Make the next test count
Before you commit lab time,
clarify the evidence.
Bring a compound, a GBM-relevant question, and the decision you need to make. Start by checking the available brief offerings.
Find your next step ↗